The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral Anti-Diabetic Drug Market Research Report 2025
Synopsis
Anti-diabetic drug refers to the medications consumed orally that are prescribed to treat diabetes mellitus (type 2). It treats diabetes (type 2) by lowering down the blood sugar level. These are also known as oral hypoglycemic agents or oral antihyperglycemic agents. Oral anti-diabetic drugs are often prescribed as monotherapy but in severe cases, can be given in combination with insulin.
The global Oral Anti-Diabetic Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Anti-Diabetic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Anti-Diabetic Drug.
Report Scope
The Oral Anti-Diabetic Drug market size, estimations, and forecasts are provided in terms of sales volume (K Tons) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Anti-Diabetic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Anti-Diabetic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Pfizer
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
Merck And Co.
AstraZeneca
Bristol Myers Squibb
Novartis
Sanofi
Abbott
Biocon
Segment by Type
Glimepiride
Gliclazide
Glyburide
Others
Segment by Application
Hospital
Research Institual
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Anti-Diabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Anti-Diabetic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Anti-diabetic drug refers to the medications consumed orally that are prescribed to treat diabetes mellitus (type 2). It treats diabetes (type 2) by lowering down the blood sugar level. These are also known as oral hypoglycemic agents or oral antihyperglycemic agents. Oral anti-diabetic drugs are often prescribed as monotherapy but in severe cases, can be given in combination with insulin.
The global Oral Anti-Diabetic Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oral Anti-Diabetic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Anti-Diabetic Drug.
Report Scope
The Oral Anti-Diabetic Drug market size, estimations, and forecasts are provided in terms of sales volume (K Tons) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oral Anti-Diabetic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oral Anti-Diabetic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Pfizer
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
Merck And Co.
AstraZeneca
Bristol Myers Squibb
Novartis
Sanofi
Abbott
Biocon
Segment by Type
Glimepiride
Gliclazide
Glyburide
Others
Segment by Application
Hospital
Research Institual
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oral Anti-Diabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oral Anti-Diabetic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oral Anti-Diabetic Drug Market Overview
1.1 Product Overview and Scope of Oral Anti-Diabetic Drug
1.2 Oral Anti-Diabetic Drug Segment by Type
1.2.1 Global Oral Anti-Diabetic Drug Market Value Comparison by Type (2024-2030)
1.2.2 Glimepiride
1.2.3 Gliclazide
1.2.4 Glyburide
1.2.5 Others
1.3 Oral Anti-Diabetic Drug Segment by Application
1.3.1 Global Oral Anti-Diabetic Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Research Institual
1.4 Global Oral Anti-Diabetic Drug Market Size Estimates and Forecasts
1.4.1 Global Oral Anti-Diabetic Drug Revenue 2019-2030
1.4.2 Global Oral Anti-Diabetic Drug Sales 2019-2030
1.4.3 Global Oral Anti-Diabetic Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oral Anti-Diabetic Drug Market Competition by Manufacturers
2.1 Global Oral Anti-Diabetic Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oral Anti-Diabetic Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oral Anti-Diabetic Drug Average Price by Manufacturers (2019-2024)
2.4 Global Oral Anti-Diabetic Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oral Anti-Diabetic Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Anti-Diabetic Drug, Product Type & Application
2.7 Oral Anti-Diabetic Drug Market Competitive Situation and Trends
2.7.1 Oral Anti-Diabetic Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Anti-Diabetic Drug Players Market Share by Revenue
2.7.3 Global Oral Anti-Diabetic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Anti-Diabetic Drug Retrospective Market Scenario by Region
3.1 Global Oral Anti-Diabetic Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oral Anti-Diabetic Drug Global Oral Anti-Diabetic Drug Sales by Region: 2019-2030
3.2.1 Global Oral Anti-Diabetic Drug Sales by Region: 2019-2024
3.2.2 Global Oral Anti-Diabetic Drug Sales by Region: 2025-2030
3.3 Global Oral Anti-Diabetic Drug Global Oral Anti-Diabetic Drug Revenue by Region: 2019-2030
3.3.1 Global Oral Anti-Diabetic Drug Revenue by Region: 2019-2024
3.3.2 Global Oral Anti-Diabetic Drug Revenue by Region: 2025-2030
3.4 North America Oral Anti-Diabetic Drug Market Facts & Figures by Country
3.4.1 North America Oral Anti-Diabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oral Anti-Diabetic Drug Sales by Country (2019-2030)
3.4.3 North America Oral Anti-Diabetic Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Oral Anti-Diabetic Drug Market Facts & Figures by Country
3.5.1 Europe Oral Anti-Diabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oral Anti-Diabetic Drug Sales by Country (2019-2030)
3.5.3 Europe Oral Anti-Diabetic Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Anti-Diabetic Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Anti-Diabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oral Anti-Diabetic Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Oral Anti-Diabetic Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Oral Anti-Diabetic Drug Market Facts & Figures by Country
3.7.1 Latin America Oral Anti-Diabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oral Anti-Diabetic Drug Sales by Country (2019-2030)
3.7.3 Latin America Oral Anti-Diabetic Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Anti-Diabetic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Anti-Diabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oral Anti-Diabetic Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oral Anti-Diabetic Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Oral Anti-Diabetic Drug Sales by Type (2019-2030)
4.1.1 Global Oral Anti-Diabetic Drug Sales by Type (2019-2024)
4.1.2 Global Oral Anti-Diabetic Drug Sales by Type (2025-2030)
4.1.3 Global Oral Anti-Diabetic Drug Sales Market Share by Type (2019-2030)
4.2 Global Oral Anti-Diabetic Drug Revenue by Type (2019-2030)
4.2.1 Global Oral Anti-Diabetic Drug Revenue by Type (2019-2024)
4.2.2 Global Oral Anti-Diabetic Drug Revenue by Type (2025-2030)
4.2.3 Global Oral Anti-Diabetic Drug Revenue Market Share by Type (2019-2030)
4.3 Global Oral Anti-Diabetic Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oral Anti-Diabetic Drug Sales by Application (2019-2030)
5.1.1 Global Oral Anti-Diabetic Drug Sales by Application (2019-2024)
5.1.2 Global Oral Anti-Diabetic Drug Sales by Application (2025-2030)
5.1.3 Global Oral Anti-Diabetic Drug Sales Market Share by Application (2019-2030)
5.2 Global Oral Anti-Diabetic Drug Revenue by Application (2019-2030)
5.2.1 Global Oral Anti-Diabetic Drug Revenue by Application (2019-2024)
5.2.2 Global Oral Anti-Diabetic Drug Revenue by Application (2025-2030)
5.2.3 Global Oral Anti-Diabetic Drug Revenue Market Share by Application (2019-2030)
5.3 Global Oral Anti-Diabetic Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Oral Anti-Diabetic Drug Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Oral Anti-Diabetic Drug Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Corporation Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly Oral Anti-Diabetic Drug Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Janssen Pharmaceuticals
6.4.1 Janssen Pharmaceuticals Corporation Information
6.4.2 Janssen Pharmaceuticals Description and Business Overview
6.4.3 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Product Portfolio
6.4.5 Janssen Pharmaceuticals Recent Developments/Updates
6.5 Astellas
6.5.1 Astellas Corporation Information
6.5.2 Astellas Description and Business Overview
6.5.3 Astellas Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Astellas Oral Anti-Diabetic Drug Product Portfolio
6.5.5 Astellas Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim Oral Anti-Diabetic Drug Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Merck And Co.
6.6.1 Merck And Co. Corporation Information
6.6.2 Merck And Co. Description and Business Overview
6.6.3 Merck And Co. Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck And Co. Oral Anti-Diabetic Drug Product Portfolio
6.7.5 Merck And Co. Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AstraZeneca Oral Anti-Diabetic Drug Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Bristol Myers Squibb
6.9.1 Bristol Myers Squibb Corporation Information
6.9.2 Bristol Myers Squibb Description and Business Overview
6.9.3 Bristol Myers Squibb Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bristol Myers Squibb Oral Anti-Diabetic Drug Product Portfolio
6.9.5 Bristol Myers Squibb Recent Developments/Updates
6.10 Novartis
6.10.1 Novartis Corporation Information
6.10.2 Novartis Description and Business Overview
6.10.3 Novartis Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Novartis Oral Anti-Diabetic Drug Product Portfolio
6.10.5 Novartis Recent Developments/Updates
6.11 Sanofi
6.11.1 Sanofi Corporation Information
6.11.2 Sanofi Oral Anti-Diabetic Drug Description and Business Overview
6.11.3 Sanofi Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sanofi Oral Anti-Diabetic Drug Product Portfolio
6.11.5 Sanofi Recent Developments/Updates
6.12 Abbott
6.12.1 Abbott Corporation Information
6.12.2 Abbott Oral Anti-Diabetic Drug Description and Business Overview
6.12.3 Abbott Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Abbott Oral Anti-Diabetic Drug Product Portfolio
6.12.5 Abbott Recent Developments/Updates
6.13 Biocon
6.13.1 Biocon Corporation Information
6.13.2 Biocon Oral Anti-Diabetic Drug Description and Business Overview
6.13.3 Biocon Oral Anti-Diabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Biocon Oral Anti-Diabetic Drug Product Portfolio
6.13.5 Biocon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Anti-Diabetic Drug Industry Chain Analysis
7.2 Oral Anti-Diabetic Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Anti-Diabetic Drug Production Mode & Process
7.4 Oral Anti-Diabetic Drug Sales and Marketing
7.4.1 Oral Anti-Diabetic Drug Sales Channels
7.4.2 Oral Anti-Diabetic Drug Distributors
7.5 Oral Anti-Diabetic Drug Customers
8 Oral Anti-Diabetic Drug Market Dynamics
8.1 Oral Anti-Diabetic Drug Industry Trends
8.2 Oral Anti-Diabetic Drug Market Drivers
8.3 Oral Anti-Diabetic Drug Market Challenges
8.4 Oral Anti-Diabetic Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
